Faron Pharmaceuticals Oy (AIM:FARN): Should The Recent EPS Drop Worry You?

Examining Faron Pharmaceuticals Oy’s (AIM:FARN) past track record of performance is an insightful exercise for investors. It allows us to reflect on whether or not the company has met or exceed expectations, which is a great indicator for future performance. Today I will assess FARN’s latest performance announced on 30 June 2017 and compare these figures to its longer term trend and industry movements. Check out our latest analysis for Faron Pharmaceuticals Oy

Was FARN’s recent earnings decline worse than the long-term trend and the industry?

I like to use data from the most recent 12 months, which annualizes the most recent half-year data, or in some cases, the latest annual report is already the most recent financial year data. This enables me to examine various companies on a more comparable basis, using the latest information. Faron Pharmaceuticals Oy’s most recent bottom-line -€12.8M, which compared to the previous year’s level, has become more negative. Since these figures may be somewhat short-term thinking, I have calculated an annualized five-year value for Faron Pharmaceuticals Oy’s earnings, which stands at -€6.0M. This doesn’t seem to paint a better picture, since earnings seem to have gradually been getting more and more negative over time.

AIM:FARN Income Statement Dec 7th 17
AIM:FARN Income Statement Dec 7th 17
Additionally, we can evaluate Faron Pharmaceuticals Oy’s loss by researching what has been happening in the industry as well as within the company. Firstly, I want to quickly look into the line items. Revenue growth over last couple of years has rose by 11.64%, implying that Faron Pharmaceuticals Oy is in a high-growth phase with expenses shooting ahead of elevated top-line growth rates. Scanning growth from a sector-level, the UK biotechnology industry has been growing its average earnings by double-digit 25.81% over the prior year, and a more subdued 7.44% over the past couple of years. This shows that any tailwind the industry is enjoying, Faron Pharmaceuticals Oy has not been able to gain as much as its industry peers.

What does this mean?

Faron Pharmaceuticals Oy’s track record can be a valuable insight into its earnings performance, but it certainly doesn’t tell the whole story. Companies that incur net loss is always hard to forecast what will happen in the future and when. The most valuable step is to examine company-specific issues Faron Pharmaceuticals Oy may be facing and whether management guidance has dependably been met in the past. I recommend you continue to research Faron Pharmaceuticals Oy to get a more holistic view of the stock by looking at:

1. Future Outlook: What are well-informed industry analysts predicting for FARN’s future growth? Take a look at our free research report of analyst consensus for FARN’s outlook.

2. Financial Health: Is FARN’s operations financially sustainable? Balance sheets can be hard to analyze, which is why we’ve done it for you. Check out our financial health checks here.

3. Other High-Performing Stocks: Are there other stocks that provide better prospects with proven track records? Explore our free list of these great stocks here.

NB: Figures in this article are calculated using data from the last twelve months, which refer to the 12-month period ending on the last date of the month the financial statement is dated. This may not be consistent with full year annual report figures.